AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15069048 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 5 ppm
Number of subjects: 385
Study 15069048 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrogen gas)
Number of subjects: 385
Study 11147718 — intervention group
Group type: EXPERIMENTAL
Intervention: buserelin MP 1.8 mg
Number of subjects: 67
Study 11147718 — intervention group
Group type: EXPERIMENTAL
Intervention: leuprolide 1.88 mg
Number of subjects: 67
Study 9313717 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofragmentable anastomosis ring (BAR)
Number of subjects: 100
Study 9313717 — intervention group
Group type: COMPARATOR
Intervention: Standard suture technique
Number of subjects: 100
Study 8324141 — intervention group
Group type: EXPERIMENTAL
Intervention: Accu-CulShure system
Number of subjects: 10
Study 8324141 — intervention group
Group type: COMPARATOR
Intervention: B-D Port-a-Cul tube
Number of subjects: 10
Study 3096429 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 45
Study 3096429 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple insulin injections (five or six daily)
Number of subjects: 45
Study 3096429 — intervention group
Group type: COMPARATOR
Intervention: Conventional twice daily insulin injections
Number of subjects: 45
Study 29362371 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX+/‐cetuximab
Number of subjects: 97
Study 28077531 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.5 mmol kg‐1 for 1 h upon induction of anaesthesia followed by 0.15 mmol kg‐1 h‐1 for 23 h)
Number of subjects: 162
Study 28077531 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 162
Study 28077531 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 162
Study 24918556 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg daily for 8 weeks
Number of subjects: 170
Study 24918556 — intervention group
Group type: COMPARATOR
Intervention: Lymecycline 300 mg daily for 8 weeks
Number of subjects: 170
Study 22380717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 23
Study 22380717 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hydroxycyclophosphamide
Number of subjects: 23
Study 20453567 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program for asthma patients
Number of subjects: 79
Study 20453567 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 79
Study 18534327 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw palmetto extract (160 mg twice daily)
Number of subjects: 225
Study 18534327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 15920008 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for acute lymphoblastic leukemia (ALL)
Number of subjects: 73
Study 12545299 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele‐ECG (12-lead ECG recorded by patients and transmitted via telephone)
Number of subjects: 128
Study 12545299 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele‐ECG
Number of subjects: 128
Study 9893189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone 100 microg administered twice daily for 4 weeks
Number of subjects: 20
Study 9893189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8908414 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination (MMSE)
Number of subjects: 1947
Study 8908414 — intervention group
Group type: EXPERIMENTAL
Intervention: Mattis Dementia Rating Scale (MDRS)
Number of subjects: 1947
Study 1885267 — intervention group
Group type: EXPERIMENTAL
Intervention: 100ml orange juice with dissolved K‐ and Mg‐phosphates (K, 40mmol; Mg, 17.5mmol; HPO4, 35mmol)
Number of subjects: 36
Study 1885267 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of ephedrine intravenously, 0.25mg/kg body weight
Number of subjects: 36
Study 1885267 — intervention group
Group type: EXPERIMENTAL
Intervention: 100ml orange juice
Number of subjects: 36
Study 1885267 — intervention group
Group type: COMPARATOR
Intervention: 100ml of water with electrolytes as in group I
Number of subjects: 36
Study 6395614 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (two-dose perioperative course, rectally administered)
Number of subjects: 198
Study 6395614 — intervention group
Group type: EXPERIMENTAL
Intervention: T-tube suction drainage
Number of subjects: 198
Study 6395614 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metronidazole and T-tube suction drainage
Number of subjects: 198
Study 6395614 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole alone
Number of subjects: 198
Study 6395614 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage alone
Number of subjects: 198
Study 6395614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 198
Study 31631008 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of silent ipsilateral brain ischaemia on magnetic resonance diffusion weighted imaging (MR-DWI)
Number of subjects: 53
Study 31631008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraplaque haemorrhage (IPH) presence
Number of subjects: 53
Study 31631008 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression analysis correcting for age and type of index event
Number of subjects: 53
Study 30126393 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation (ORIF) for non-dislocated Lisfranc injuries
Number of subjects: 0
Study 30126393 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Arthrodesis (PA) for dislocated Lisfranc injuries
Number of subjects: 0
Study 30126393 — intervention group
Group type: COMPARATOR
Intervention: Cast-immobilization for non-dislocated Lisfranc injuries
Number of subjects: 0
Study 30126393 — intervention group
Group type: COMPARATOR
Intervention: Open Reduction and Internal Fixation (ORIF) for dislocated Lisfranc injuries
Number of subjects: 0
Study 27112632 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream applied 3 times per week for 12 weeks
Number of subjects: 8
Study 27112632 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream
Number of subjects: 8
Study 24981390 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation associated with an infectious diseases (ID) specialist intervention
Number of subjects: 249
Study 24981390 — intervention group
Group type: COMPARATOR
Intervention: Simple presentation of audit feedback and guidelines
Number of subjects: 249
Study 21678095 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP group (n=20)
Number of subjects: 40
Study 21678095 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 40
Study 20626240 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 2550 mg/day
Number of subjects: 75
Study 20626240 — intervention group
Group type: COMPARATOR
Intervention: Acarbose 300 mg/day
Number of subjects: 75
Study 17716550 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (75 g)
Number of subjects: 19
Study 17716550 — intervention group
Group type: COMPARATOR
Intervention: Sham isovolumetric unsweetened drink
Number of subjects: 19
Study 15800139 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 5386
Study 15800139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5386
Study 15800139 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 5386
Study 12576260 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg per day) + Conjugated estrogen cream (0.5 g)
Number of subjects: 187
Study 12576260 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg per day) + Nonhormonal moisturizer
Number of subjects: 187
Study 12576260 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Conjugated estrogen cream (0.5 g)
Number of subjects: 187
Study 12576260 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Nonhormonal moisturizer
Number of subjects: 187
Study 10385578 — intervention group
Group type: COMPARATOR
Intervention: Semantic decision task
Number of subjects: 0
Study 10385578 — intervention group
Group type: COMPARATOR
Intervention: Phonological processing of words and pseudowords in a syllable-counting task
Number of subjects: 0
Study 10385578 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic processing
Number of subjects: 0
Study 8723144 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 200 mg/day
Number of subjects: 31
Study 8723144 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 600 mg/day
Number of subjects: 31
Study 8723144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 1653795 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (2 x 20 mg/day)
Number of subjects: 33
Study 1653795 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergine (2 x 2 mg/day)
Number of subjects: 33
Study 1653795 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Nifedipine 20 mg/day and Hydergine 2 mg/day, twice daily each)
Number of subjects: 33
Study 6805588 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg/day
Number of subjects: 9
Study 6805588 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/day
Number of subjects: 9
Study 6805588 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg/day
Number of subjects: 9
Study 6805588 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg/day
Number of subjects: 9
Study 31907776 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV1 expression at primary site
Number of subjects: 80
Study 31907776 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV1 expression at metastatic lymph nodes
Number of subjects: 80
Study 31764099 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 4572
Study 31764099 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 4572
Study 28294173 — intervention group
Group type: EXPERIMENTAL
Intervention: UHT dairy milk (1.5 l for 21 days)
Number of subjects: 19
Study 28294173 — intervention group
Group type: COMPARATOR
Intervention: PAST dairy milk (1.5 l for 21 days)
Number of subjects: 19
Study 25750102 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention with participation of patients
Number of subjects: 946
Study 25750102 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 946
Study 22568828 — intervention group
Group type: EXPERIMENTAL
Intervention: FPSM/BDP (Fluticasone/Salmeterol + HFA-beclomethasone diproprionate 200 µg twice daily)
Number of subjects: 15
Study 22568828 — intervention group
Group type: EXPERIMENTAL
Intervention: FPSM/PRED (Fluticasone/Salmeterol + Prednisolone 25 mg day(‐1) for 1 week)
Number of subjects: 15
Study 22568828 — intervention group
Group type: COMPARATOR
Intervention: FPSM (Fluticasone/Salmeterol)
Number of subjects: 15
Study 22568828 — intervention group
Group type: EXPERIMENTAL
Intervention: FPSM/FP (Fluticasone/Salmeterol + Fluticasone 250 µg twice daily)
Number of subjects: 15
Study 22568828 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP (HFA-beclomethasone diproprionate 200 µg twice daily)
Number of subjects: 15
Study 20733587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 to 100 mg, adjustable to 25 mg)
Number of subjects: 129
Study 20733587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 19330598 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized estradiol (E2) 0.5 mg
Number of subjects: 211
Study 19330598 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized estradiol (E2) 1.0 mg
Number of subjects: 211
Study 19330598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 17100738 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT
Number of subjects: 45
Study 17100738 — intervention group
Group type: COMPARATOR
Intervention: Placebo-PDT
Number of subjects: 45
Study 15080865 — intervention group
Group type: EXPERIMENTAL
Intervention: MIDCAB
Number of subjects: 100
Study 15080865 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 100
Study 11590497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis
Number of subjects: 0
Study 11590497 — intervention group
Group type: EXPERIMENTAL
Intervention: Imputation of missing data values
Number of subjects: 0
Study 9284696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy (400 mg/day for 2 weeks followed by 500 mg/day elemental calcium for 11 weeks)
Number of subjects: 54
Study 9284696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy
Number of subjects: 54
Study 9284696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 9284696 — intervention group
Group type: EXPERIMENTAL
Intervention: Former etidronate group (1-year follow-up)
Number of subjects: 54
Study 8335459 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural interferon beta (5 million IU, 30-min i.v. infusion, three times weekly for 6 months)
Number of subjects: 105
Study 8335459 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated symptomatic controls)
Number of subjects: 105
Study 3594459 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiracetam (2 X 800 mg, orally, bid for 8 weeks)
Number of subjects: 43
Study 3594459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally, bid for 8 weeks)
Number of subjects: 43
Study 29720365 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 81
Study 24252795 — intervention group
Group type: EXPERIMENTAL
Intervention: Large bowl (16 oz)
Number of subjects: 87
Study 24252795 — intervention group
Group type: COMPARATOR
Intervention: Small bowl (8 oz)
Number of subjects: 87
Study 22236339 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based coping
Number of subjects: 0
Study 22236339 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of emotions
Number of subjects: 0
Study 22236339 — intervention group
Group type: COMPARATOR
Intervention: No instructions (control group)
Number of subjects: 0
Study 21302490 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy + Smecta + Umbilical application of Lunxieting Paste (LXT) (Group C)
Number of subjects: 190
Study 21302490 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy + Smecta (Group B)
Number of subjects: 190
Study 21302490 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only (Group A)
Number of subjects: 190
Study 17967831 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg i.v. every 6 weeks)
Number of subjects: 69
Study 16388068 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialised care by the early onset team
Number of subjects: 144
Study 16388068 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 144
Study 12562457 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei supplementation (10^8 colony-forming units/mL L. casei, thrice daily during meals for 3 weeks)
Number of subjects: 14
Study 12562457 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 untreated H. pylori-positive subjects)
Number of subjects: 14
Study 10801757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary gamma-radiation therapy (15 Gy)
Number of subjects: 130
Study 8633574 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (660 mg/day)
Number of subjects: 30
Study 8633574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1455853 — intervention group
Group type: EXPERIMENTAL
Intervention: Polnitrin (5 mg nitroglycerin buccal tablet)
Number of subjects: 0
Study 1455853 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreign analogue (5 mg nitroglycerin buccal tablet)
Number of subjects: 0
Study 1455853 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.5 mg tablet)
Number of subjects: 0
Study 1455853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3968773 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine monophosphate (AMP) treatment
Number of subjects: 32
Study 3968773 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 32
Study 29605353 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary rhinoseptoplasty (Group A)
Number of subjects: 40
Study 29605353 — intervention group
Group type: COMPARATOR
Intervention: No rhinoseptal correction (Group B)
Number of subjects: 40
Study 27614124 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice in addition to the clarithromycin‐based triple regimen for two weeks
Number of subjects: 120
Study 27614124 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin‐based triple regimen
Number of subjects: 120
Study 25543323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure™
Number of subjects: 94
Study 25543323 — intervention group
Group type: COMPARATOR
Intervention: Harmonic Ace®
Number of subjects: 94
Study 24148131 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV initiation after tuberculosis treatment onset
Number of subjects: 0
Study 24148131 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18603575 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 16
Study 18603575 — intervention group
Group type: COMPARATOR
Intervention: Sham-Inspiratory Muscle Training (sham-IMT)
Number of subjects: 16
Study 18603575 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IMT and sham-IMT
Number of subjects: 16
Study 18958979 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who could leave feedback regarding the outcome of their interaction with their partner
Number of subjects: 0
Study 18958979 — intervention group
Group type: COMPARATOR
Intervention: Participants who could not leave feedback regarding the outcome of their interaction with their partner
Number of subjects: 0
Study 15860983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of amlodipine besylate/benazepril HCl
Number of subjects: 20
Study 15860983 — intervention group
Group type: COMPARATOR
Intervention: Enalapril monotherapy
Number of subjects: 20
Study 15860983 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 20
Study 12770641 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance-training program (24 weeks)
Number of subjects: 45
Study 12770641 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=16)
Number of subjects: 45
Study 10479469 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (Cebran((R)), 2 cps day) for 30 days
Number of subjects: 60
Study 10479469 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 8736714 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat‐washout method in thumb
Number of subjects: 22
Study 8736714 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat‐washout method in first toe
Number of subjects: 22
Study 8736714 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat‐washout method in ear lobe and nose
Number of subjects: 22
Study 1880885 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity group-based exercise training
Number of subjects: 357
Study 1880885 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity home-based exercise training
Number of subjects: 357
Study 1880885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-intensity home-based exercise training
Number of subjects: 357
Study 1880885 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 357
Study 1880885 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training (both higher and lower intensity)
Number of subjects: 357
Study 6213250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.5 mg)
Number of subjects: 8
Study 6213250 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (2 mg)
Number of subjects: 8
Study 6213250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide and fenoterol (combination)
Number of subjects: 8
Study 6213250 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 6213250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide and fenoterol (both drugs)
Number of subjects: 8
Study 30762760 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) tranexamic acid (TXA) 20 mg/kg before TKA
Number of subjects: 150
Study 30762760 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular (IA) tranexamic acid (TXA) 3.0 g after TKA
Number of subjects: 150
Study 30762760 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IV (20 mg/kg) and IA (3.0 g) tranexamic acid (TXA)
Number of subjects: 150
Study 27856940 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational cigarettes with 0.4 mg/g nicotine content
Number of subjects: 839
Study 27856940 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational cigarettes with 0.4 mg/g high tar nicotine content
Number of subjects: 839
Study 27856940 — intervention group
Group type: COMPARATOR
Intervention: Control group (15.8 mg/g nicotine content)
Number of subjects: 839
Study 27322475 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP with best supportive care (BSC)
Number of subjects: 55
Study 27322475 — intervention group
Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 55
Study 25326074 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 149
Study 25326074 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 149
Study 25326074 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (mHealth and active control)
Number of subjects: 149
Study 21658783 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZoMaxx)
Number of subjects: 1099
Study 21658783 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (Taxus)
Number of subjects: 1099
Study 19164458 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET after two cycles of chemotherapy
Number of subjects: 51